TimiHealth launched the TimiDNA platform as a direct response to 23andMe and other genetic testing companies who are selling genetic data for unintended financial benefit without the understood permission of consumers or profit sharing with them.
This was highlighted by the announced $300 million dollar 50/50 partnership deal between 23andMe and GlaxoSmithKline (GSK) (https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines). It was further exacerbated by the restrictions placed on their API program as described by the following statement sent to consumers:
“Moving forward, we’ve decided to restrict our API to only work with select applications that will use the data based on 23andMe reports to bring added value to your overall experience. Based on these changes, in two weeks, we will be disabling other apps’ ability to access your data using the 23andMe API, and any features in those third-party apps that rely on your 23andMe data may no longer work.”
TimiHealth is supporting consumers who have expressed deep disappointment and anger in the misrepresentation of services for the collection and sale of their genetic DNA data through sponsorship of “Where’s Your DNA? Petition at www.wheresyourdna.com.
If you are an affected genetic consumer who believes you should own and control your DNA data and have the right to participate in the financial sale of your data if you so choose, sign the petition and have your voice heard. Nothing defines you more than your DNA and understanding how it is being used or sold is paramount to the issue of personal data security.